Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2019’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

– The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects

– The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“ABIONYX Pharma SA

Acea Biotech Inc

Biokawthar Technologies SAS

BioLingus AG

Daiichi Sankyo Co Ltd

DetectoGen Inc

Eurofins Advinus Ltd

GlaxoSmithKline Plc

iCo Therapeutics Inc

Immune Modulation Inc

Laboratorios LETI SL

Macrophage Therapeutics Inc

ManRos Therapeutics

Matinas BioPharma Holdings Inc

Mind Medicine Inc

Molecular Targeting Technologies Inc

Mycosynthetix Inc

NanoCliq LLC

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Pai Life Sciences Inc

Pfizer Inc

Pharos I&BT Co Ltd

Phi Pharma SA

Rakta Therapeutics Inc

Sequella Inc

Synstar Japan Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Leishmaniasis (Kala-Azar) Overview 6

Leishmaniasis (Kala-Azar) Therapeutics Development 7

Leishmaniasis (Kala-Azar) Therapeutics Assessment 18

Leishmaniasis (Kala-Azar) Companies Involved in Therapeutics Development 26

Leishmaniasis (Kala-Azar) Drug Profiles 33

Leishmaniasis (Kala-Azar) Dormant Projects 105

Leishmaniasis (Kala-Azar) Discontinued Products 107

Leishmaniasis (Kala-Azar) Product Development Milestones 108

Appendix 117

List of Tables

“List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by ABIONYX Pharma SA, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Acea Biotech Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Biokawthar Technologies SAS, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by DetectoGen Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Eurofins Advinus Ltd, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by GlaxoSmithKline Plc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by iCo Therapeutics Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Immune Modulation Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Laboratorios LETI SL, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Macrophage Therapeutics Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Mind Medicine Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Molecular Targeting Technologies Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Mycosynthetix Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by NanoCliq LLC, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Pai Life Sciences Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Pfizer Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Pharos I&BT Co Ltd, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Phi Pharma SA, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Rakta Therapeutics Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Sequella Inc, H2 2019

Leishmaniasis (Kala-Azar) – Pipeline by Synstar Japan Co Ltd, H2 2019

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2019

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2019 (Contd..2), H2 2019

Leishmaniasis (Kala-Azar) – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports